225 related articles for article (PubMed ID: 37124623)
81. A cuproptosis-associated long non-coding RNA signature for the prognosis and immunotherapy of lung squamous cell carcinoma.
Hou C; Wu X; Li C; Wang C; Liu J; Luo Q
Biomol Biomed; 2023 Jul; 23(4):624-633. PubMed ID: 36724022
[TBL] [Abstract][Full Text] [Related]
82. A novel cuproptosis-related lncRNA signature predicts prognosis and therapeutic response in bladder cancer.
Cai J; Xie H; Yan Y; Huang Z; Tang P; Cao X; Wang Z; Yang C; Wen J; Tan M; Zhang F; Shen B
Front Genet; 2022; 13():1082691. PubMed ID: 36685947
[TBL] [Abstract][Full Text] [Related]
83. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma.
Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J
Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546
[TBL] [Abstract][Full Text] [Related]
84. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis.
Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L
BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550
[TBL] [Abstract][Full Text] [Related]
85. Identification of cuproptosis-related long non-coding ribonucleic acid signature as a novel prognosis model for colon cancer.
Xu R; Wu X; Du A; Zhao Q; Huang H
Am J Cancer Res; 2022; 12(11):5241-5254. PubMed ID: 36504883
[TBL] [Abstract][Full Text] [Related]
86. Development and validation of a cuproptosis-related lncRNA model correlated to the cancer-associated fibroblasts enable the prediction prognosis of patients with osteosarcoma.
Wang X; Xie C; Lin L
J Bone Oncol; 2023 Feb; 38():100463. PubMed ID: 36569351
[TBL] [Abstract][Full Text] [Related]
87. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
[TBL] [Abstract][Full Text] [Related]
88. Cuproptosis-related LncRNAs signature as biomarker of prognosis and immune infiltration in pancreatic cancer.
Chen H; Yu Y; Zhou L; Chen J; Li Z; Tan X
Front Genet; 2023; 14():1049454. PubMed ID: 36713077
[No Abstract] [Full Text] [Related]
89. A Newly Established Cuproptosis-Associated Long Non-Coding RNA Signature for Predicting Prognosis and Indicating Immune Microenvironment Features in Soft Tissue Sarcoma.
Han J; Hu Y; Liu S; Jiang J; Wang H
J Oncol; 2022; 2022():8489387. PubMed ID: 35847354
[TBL] [Abstract][Full Text] [Related]
90. Distinct tumor microenvironment landscapes in gastric cancer classified by cuproptosis-related lncRNAs.
Huang J; Chen M; Pei W; Xu Z; Ning J; Chen C
J Cancer; 2022; 13(15):3687-3700. PubMed ID: 36606199
[TBL] [Abstract][Full Text] [Related]
91. Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer.
Li W; Zhang X; Chen Y; Pang D
Front Oncol; 2022; 12():966511. PubMed ID: 36212436
[TBL] [Abstract][Full Text] [Related]
92. A prognostic cuproptosis-related lncRNA predictive signature for bladder cancer patients.
Jiang S; Zhang J; Fan Q; Li Z; Dou R; Lin Z; Chen Z; Xu Y; Huang Z; Lan J; Lin W; Xu S; Gao X; Li M
Hum Cell; 2023 Mar; 36(2):798-811. PubMed ID: 36709471
[TBL] [Abstract][Full Text] [Related]
93. Identification of two molecular subtypes and a novel prognostic model of lung adenocarcinoma based on a cuproptosis-associated gene signature.
Zhou J; Chen D; Zhang S; Wang C; Zhang L
Front Genet; 2022; 13():1039983. PubMed ID: 36712848
[TBL] [Abstract][Full Text] [Related]
94. Development and Evaluation of a Novel Cuproptosis-Related lncRNA Signature for Gastric Cancer Prognosis.
Yin C; Gao M; Wang Q; Li H
Comput Math Methods Med; 2023; 2023():6354212. PubMed ID: 36820319
[TBL] [Abstract][Full Text] [Related]
95. Multi-omics analysis defines a cuproptosis-related prognostic model for ovarian cancer: Implication of WASF2 in cuproptosis resistance.
Wang K; Zhang Y; Ao M; Luo H; Mao W; Li B
Life Sci; 2023 Nov; 332():122081. PubMed ID: 37717621
[TBL] [Abstract][Full Text] [Related]
96. Cuproptosis-related LncRNAs are correlated with immunity and predict prognosis in HNSC independent of TMB.
Li M; Nurzat Y; Huang H; Min P; Zhang X
Front Genet; 2023; 14():1028044. PubMed ID: 36816017
[No Abstract] [Full Text] [Related]
97. Construction of a cuproptosis-related lncRNA signature for predicting prognosis and immune landscape in osteosarcoma patients.
Ni S; Hong J; Li W; Ye M; Li J
Cancer Med; 2023 Feb; 12(4):5009-5024. PubMed ID: 36129020
[TBL] [Abstract][Full Text] [Related]
98. Cuproptosis-related lncRNAs potentially predict prognosis and therapy sensitivity of breast cancer.
Wu X; Zhang Y; Liang G; Ye H
Front Pharmacol; 2023; 14():1199883. PubMed ID: 37529698
[No Abstract] [Full Text] [Related]
99. Identification and validation of a seven cuproptosis-associated lncRNA signature to predict the prognosis of endometrial cancer.
Cai L; Cai L; Zhou L; Zhao Y; Qian J
J Int Med Res; 2023 Dec; 51(12):3000605231213435. PubMed ID: 38102991
[TBL] [Abstract][Full Text] [Related]
100. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
Front Oncol; 2023; 13():972558. PubMed ID: 37064115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
